MIST NASDAQ
Milestone Pharmaceuticals Inc.
1W: +2.7%
1M: -31.4%
3M: -38.7%
YTD: -55.5%
1Y: -52.1%
3Y: -72.7%
5Y: -84.9%
$0.81
-0.01 (-0.74%)
Weekly Expected Move ±8.3%
$1
$1
$1
$1
$1
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
8 relationships8
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2021-05-17
Earliest Filing
2025-07-11
Latest Filing
partner: 6
investor: 2
Counterparties (Filed by MIST)
8 relationshipsCompanies named in MIST's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| RTW Royalty I DAC | — | partner | Affiliate of RTW Investments, LP that entered into an amendment to the Royalty Purchase Agreement with Milestone Pharmac | 2025-07-11 | View |
| RTW Investments, LP | — | partner | Parent entity of RTW Royalty I DAC, an affiliate that entered into an amendment to the Royalty Purchase Agreement with M | 2025-07-11 | View |
| Jefferies LLC | JEF | partner | Sales agent for the amended open market sale agreement | 2025-03-18 | View |
| Alta Fundamental Advisers LLC | — | partner | Entered into a Cooperation Agreement to appoint new directors and coordinate voting. | 2024-07-15 | View |
| Alta Fundamental Advisers Master L.P. | — | partner | Withdrew notice of director nominations pursuant to the Cooperation Agreement. | 2024-07-15 | View |
| RTW Investments, LP | — | investor | Agreed to purchase royalty interest on etripamil sales and purchase convertible notes. | 2023-03-28 | View |
| Ji Xing Pharmaceuticals, Limited | — | partner | Entered into a License and Collaboration Agreement for exclusive development and commercialization rights to etripamil n | 2021-05-17 | View |
| RTW Investments, LP | — | investor | Beneficial owner of approximately 14% of the Company's common shares and affiliate of Ji Xing Pharmaceuticals, Limited. | 2021-05-17 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-03 | Other Events; Exhibits | View | |
| 2026-08-12 | Earnings Release; Exhibits | View | |
| 2026-06-15 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-13 | Earnings Release; Exhibits | View | |
| 2026-01-26 | Other Events; Financial Statements and Exhibits | View | |
| 2026-01-13 | Other Events | View | |
| 2026-01-06 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-15 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-14 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-07-11 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-06-16 | Other Events; Financial Statements and Exhibits | View | |
| 2025-06-12 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-28 | Other Events; Financial Statements and Exhibits | View | |
| 2025-03-19 | Shareholder Nominations | View | |
| 2025-03-18 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-03-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-25 | Regulation FD Disclosure; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR